

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/00		A2	(11) International Publication Number: WO 98/02151
(21) International Application Number: PCT/US97/12120			(43) International Publication Date: 22 January 1998 (22.01.98)
(22) International Filing Date: 11 July 1997 (11.07.97)			
(30) Priority Data: 60/021,716 12 July 1996 (12.07.96)		US	
(71) Applicant: LEUKOSITE, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(72) Inventors: SCHWENDER, Charles, F.; 577 East Hill Road, Glen Gardner, NJ 08826 (US). MACKAY, Charles, R.; 126 Church Street, Watertown, MA 02172 (US). PINTO, Julia, C.; 8 Chubb's Brook Lane, Beverly Farms, MA 01915 (US). NEWMAN, Walter; 8 Durham Street No. 3, Boston, MA 02115 (US).			Published <i>Without international search report and to be republished upon receipt of that report.</i>
(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02173 (US).			

(54) Title: CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR

(57) Abstract

Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by structural formula (I) and physiologically acceptable salts thereof. Z is a substituted or unsubstituted aromatic group. Y is a covalent bond, -O- or -CO-. n is an integer from one to about five. X is a covalent bond or -CO-. R_a is an aliphatic or a substituted aliphatic group; R_b is an aliphatic group substituted with an aromatic group or substituted aromatic group; and, taken together with the nitrogen atom bonded to R_a and R_b, can form a substituted or unsubstituted non-aromatic heterocyclic ring.



AQ7

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

CHEMOKINE RECEPTOR ANTAGONISTS
AND METHODS OF USE THEREFOR

BACKGROUND OF THE INVENTION

Chemoattractant cytokines or chemokines are a family
5 of proinflammatory mediators that promote recruitment and
activation of multiple lineages of leukocytes and
lymphocytes. They can be released by many kinds of tissue
cells after activation. Continuous release of chemokines at
sites of inflammation mediates the ongoing migration of
10 effector cells in chronic inflammation. The chemokines
characterized to date are related in primary structure.
They share four conserved cysteines, which form disulfide
bonds. Based upon this conserved cysteine motif, the family
is divided into two main branches, designated as the C-X-C
15 chemokines (α -chemokines), and the C-C chemokines
(β -chemokines), in which the first two conserved cysteines
are separated by an intervening residue, or adjacent
respectively (Baggiolini, M. and Dahinden, C. A.,
Immunology Today, 15:127-133 (1994)).

20 The C-X-C chemokines include a number of potent
chemoattractants and activators of neutrophils, such as
interleukin 8 (IL-8), PF4 and neutrophil-activating
peptide-2 (NAP-2). The C-C chemokines include RANTES
(Regulated on Activation, Normal T Expressed and
25 Secreted), the macrophage inflammatory proteins 1 α and 1 β

-2-

(MIP-1 α and MIP-1 β), and human monocyte chemotatic proteins 1-3 (MCP-1, MCP-2, MCP-3), which have been characterized as chemoattractants and activators of monocytes or lymphocytes but do not appear to be chemoattractants for neutrophils.

5 Chemokines, such as RANTES and MIP-1 α , have been implicated in a wide range of human acute and chronic inflammatory diseases including respiratory diseases, such as asthma and allergic disorders.

The chemokine receptors are members of a superfamily 10 of G protein-coupled receptors (GPCR) which share structural features that reflect a common mechanism of action of signal transduction (Gerard, C. and Gerard, N.P., *Annu Rev. Immunol.*, 12:775-808 (1994); Gerard, C. and Gerard, N. P., *Curr. Opin. Immunol.*, 6:140-145 (1994)).

15 Conserved features include seven hydrophobic domains spanning the plasma membrane, which are connected by hydrophilic extracellular and intracellular loops. The majority of the primary sequence homology occurs in the hydrophobic transmembrane regions with the hydrophilic 20 regions being more diverse. The first receptor for the C-C chemokines that was cloned and expressed binds the chemokines MIP-1 α and RANTES. Accordingly, this MIP-1 α /RANTES receptor was designated C-C chemokine receptor 1 (also referred to as CCR-1; Neote, K., et al., 25 *Cell*, 72:415-425 (1993); Horuk, R. et al., WO 94/11504, May 26, 1994; Gao, J.-I. et al., *J. Exp. Med.*, 177:1421-1427 (1993)). Three new receptors have been characterized which bind and/or signal in response to RANTES: CCR3 mediates binding and signaling of chemokines including eotaxin, 30 RANTES, and MCP-3 (Ponath et al., *J. Exp. Med.*, 183:2437 (1996)), CCR4 binds chemokines including RANTES, MIP-1 α , and MCP-1 (Power, et al., *J. Biol. Chem.*, 270:19495 (1995)), and CCR5 binds chemokines including MIP-1 α ,

-3-

RANTES, and MIP-1 β (Samson, et al., *Biochem.* 35: 3362-3367 (1996)). RANTES is a chemotactic chemokine for a variety of cell types, including monocytes, eosinophils, and a subset of T-cells. The responses of these different cells 5 may not all be mediated by the same receptor, and it is possible that the receptors CCR1, CCR4 and CCR5 will show some selectivity in receptor distribution and function between leukocyte types, as has already been shown for CCR3 (Ponath et al.). In particular, the ability of RANTES to 10 induce the directed migration of monocytes and a memory population of circulating T-cells (Schall, T. et al., *Nature*, 347:669-71 (1990)) suggests this chemokine and its receptor(s) may play a critical role in chronic inflammatory diseases, since these diseases are 15 characterized by destructive infiltrates of T cells and monocytes.

Many existing drugs have been developed as antagonists of the receptors for biogenic amines, for example, as antagonists of the dopamine and histamine receptors. No 20 successful antagonists have yet been developed to the receptors for the larger proteins such as chemokines and C5a. Small molecule antagonists of the interaction between C-C chemokine receptors and their ligands, including RANTES and MIP-1 α , would provide compounds useful for inhibiting 25 harmful inflammatory processes "triggered" by receptor ligand interaction, as well as valuable tools for the investigation of receptor-ligand interactions.

SUMMARY OF THE INVENTION

30 It has now been found that a number of small organic molecules are antagonists of chemokine receptor function and can inhibit leukocyte activation and/or recruitment. An antagonist of chemokine receptor function is a molecule which can inhibit the binding of one or more chemokines,

-4-

including C-C chemokines such as RANTES and MIP-1 α , to one or more chemokine receptors on leukocytes and/or other cell types. As a consequence, processes and cellular responses mediated by chemokine receptors can be inhibited with these 5 small organic molecules. Based on this discovery, a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation is disclosed. The method comprises administering to the subject a therapeutically effective amount of a compound or 10 small organic molecule which is an antagonist of chemokine receptor function. Compounds or small organic molecules which have been identified as antagonists of chemokine receptor function are discussed in detail hereinbelow, and can be used for the manufacture of a medicament for 15 treating or for preventing a disease associated with aberrant leukocyte recruitment and/or activation. The invention also relates to the disclosed compounds and small organic molecules and their use in treating or preventing a disease associated with aberrant leukocytes recruitment 20 and/or activation. The invention also includes pharmaceutical compositions comprising one or more of the compounds or small organic molecules which have been identified herein as antagonists of chemokine function and a suitable pharmaceutical carrier. The invention further 25 relates to novel compounds which can be used to treat an individual with a disease associated with aberrant leukocyte recruitment and/or activation.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A and 1B are histograms illustrating the 30 inhibition by varying concentrations of LS370 and LS374 (also referred to herein as "L-370" and "L-374", respectively) in the chemotaxis of fresh peripheral blood mononuclear cells (PBMC) in response to RANTES or MIP-1 α .

-5-

DETAILED DESCRIPTION OF THE INVENTION


The present invention relates to small molecule compounds which are antagonists of chemokine receptor function. Accordingly, processes or cellular responses mediated by the binding of a chemokine to a receptor can be inhibited (reduced or prevented, in whole or in part), including leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium $[Ca^{++}]_i$, and/or granule release of proinflammatory mediators.

The invention further relates to a method of treatment, including prophylactic and therapeutic treatments, of a disease associated with aberrant leukocyte recruitment and/or activation, including chronic inflammatory disorders characterized by the presence of RANTES and/or MIP-1 α responsive T cells, monocytes and/or eosinophils, including but not limited to diseases such as arthritis, psoriasis, multiple sclerosis, inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, as well as allergies and asthma. Other diseases associated with aberrant leukocyte recruitment and/or activation which can be treated (including prophylactic treatments) with the methods disclosed herein are inflammatory diseases associated with Human Immunodeficiency Virus (HIV) infection, e.g., AIDS associated encephalitis, AIDS related maculopapular skin eruption, AIDS related interstitial pneumonia, AIDS related enteropathy, AIDS related periportal hepatic inflammation and AIDS related glomerulo nephritis. The method comprises administering to a subject a therapeutically effective amount of a compound (i.e., one or more compounds) which inhibits chemokine receptor function, inhibits the binding of a chemokine to leukocytes and/or other cell types, and/or which inhibits leukocyte migration to, and/or activation at, sites of inflammation. According

- 6 -

to the method, chemokine-mediated chemotaxis and/or activation of pro-inflammatory cells bearing receptors for chemokines can be inhibited. As used herein, "pro-inflammatory cells" includes but is not limited to leukocytes, since chemokine receptors may be expressed on other cell types, such as neurons and epithelial cells.

In one embodiment of the present invention, the antagonist of chemokine receptor function is represented by Structural Formula (I):



(I)

Z is a substituted or unsubstituted aromatic group.

Y is a covalent bond, -O- or -CO-.

n is an integer from one to about five. n is
15 preferably one, two, or three.


X is a covalent bond or -CO-.

R_a and R_c , taken together with the nitrogen atom to which they are bonded, form a substituted or unsubstituted non-aromatic heterocyclic ring. For example, R_a and R_b , together with the nitrogen atom to which they are bonded, form a four, five, six, seven or eight-membered nitrogen-containing non-aromatic ring. Alternatively R_a is an aliphatic or a substituted aliphatic group and R_b is an aliphatic group substituted with an aromatic group or substituted aromatic group.

In a preferred embodiment, R_a and R_b , together with the nitrogen atom to which they are bonded, form a six-membered nitrogen-containing non-aromatic ring. For example, the

-7-

six-membered, nitrogen-containing non-aromatic ring can be chosen such that the antagonist of chemokine receptor function is represented by Structural Formula (II):



5

(II)


Z, Y, X and n are as described in Structural Formula (I).

M is $>NR_2$, $>CR_1R_2$, -O-, -S- or -CO-. M is preferably $>NR_2$ or $>CR_1R_2$.

R₁ is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group). Preferably, R₁ is -H or -OH.

R₂ is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.



When M is $>NR_2$ or $>CR_1R_2$, the antagonist of chemokine receptor function is preferably a compound represented by Structural Formulas (III) through (VIII):




- 8 -

(III)


(IV)



(V)



(VI)



(VII)

(VIII)

5 In Structural Formulas (III) and (IV), n is preferably one, two or three, more preferably one. When n is one and R_1 is $-H$ or $-OH$, R_2 is preferably a C_1 to about a C_4 alkyl group substituted with an aromatic or substituted aromatic group.


10 In Structural Formulas (V) and (VI), n is preferably one, two or three, more preferably two or three. When n is two or three and R_1 is $-H$ or $-OH$, R_2 is preferably an aliphatic or substituted aliphatic group, preferably an alkyl group substituted with a hydroxyl, alkoxy, thiol, or alkylthiol group.

15 In Structural Formulas (VII) and (VIII), n is preferably one, two or three, more preferably three. When n is three and R_1 is $-H$ or $-OH$, R_2 is preferably an aromatic group, a substituted aromatic group or an

- 9 -

aliphatic group substituted with an aromatic or substituted aromatic group.


In another preferred embodiment, -X- and -Y- in Structural Formula (II) are each a covalent bond and the 5 antagonist of chemokine receptor function is a compound represented by Structural Formula (IX):



(IX)

10 Z, n and M are as described above for Structural Formula (II). Preferably, Z is a tricyclic ring system comprising two carbocyclic aromatic groups fused to a seven or eight membered cycloalkyl group or to a non-aromatic heterocyclic ring. In one example, Z is represented by Structural Formula (IXa):

15



(IXa)


The phenyl rings in Structural Formula (IXa), labeled with an "A" and "B", are referred to herein as "Ring A" and "Ring B", respectively. The central ring, labeled with a 20 "C", is referred to as "Ring C" and can be, for example a seven or eight membered non-aromatic carbocyclic ring (e.g., a cycloheptane or cyclooctane ring) or a non-aromatic heterocyclic ring. When Ring C is a non-aromatic

-10-

heterocyclic ring, it can contain one or two heteroatoms such as nitrogen, sulfur or oxygen. When Z is represented by Structural Formula (IXa), the tricyclic ring system is connected to the alkylene group in Structural Formula (IX) by a single covalent bond between the alkylene group and a ring atom in Ring C which is not also in Ring A or Ring B. 5 Ring A and/or Ring B can be unsubstituted. Alternatively, Ring A and/or Ring B can have one or more substituents. Suitable substituents are as described 10 hereinbelow for substituted aromatic groups.


In addition, Ring C optionally contains one or more additional substituents, for example, R₃ and R₄. When Ring C is a non-aromatic carbocyclic ring, substituents such as R₃ and R₄ are as described hereinbelow for substituted 15 aliphatic rings. When Ring C contains one or more heteroatoms, substituents such as R₃ and R₄ are as described below for non-aromatic heterocyclic rings. Preferably, R₃ is -H and R₄ is -H or an electron 20 withdrawing group. Suitable electron withdrawing groups include -CN, alkylsulfonyl, carboxamido, carboxylic alkyl esters, -NO₂ and halogens (e.g., -Br and -Cl).

More preferably, Z in Structural Formula (IX) is represented by Structural Formulas (X) and (XI):



25

(X)



(XI)


-11-

X_1 is a chemical bond, -S-, -CH₂- or -CH₂S-. Preferably, X_1 is -S- in Structural Formula (X) and -CH₂S- in Structural Formula (XI).

W is -H or an electron withdrawing group, as described 5 above for Structural Formula (IXa). A preferred electron withdrawing group is -CN. Ring A and Ring B are as described above in Structural Formula (IXa).

When X_1 in Structural Formula (X) is -S- or when X_1 in Structural Formula (XI) is -CH₂S-, M is preferably >NR₂ or 10 >CR₁R₂. When M is >NR₂ or >CR₁R₂, W is preferably -CN and n is preferably two, three or four, more preferably three. R₁ is preferably -H or -OH.

In another preferred embodiment, R_a is an aliphatic or 15 a substituted aliphatic group and R_b is an aliphatic group substituted with an aromatic group or substituted aromatic group. As a consequence, the antagonist of chemokine receptor function is a compound represented by Structural Formula (XII):



20


(XII)

Preferably, n is an integer from about two to about four; R_a is a C₁ to about a C₄ substituted or unsubstituted alkyl group; and R_b is -(CH₂)_m-R₁₀, wherein m is an integer from about two to about four, and R₁₀ is an aromatic group.


25

In yet another preferred embodiment, the antagonist of chemokine function is a compound represented by Structural Formula (I), wherein Z is represented by Structural Formulas (X) or (XI) and -X- and -Y- are each a covalent bond. In this instance the antagonist of chemokine receptor function is a compound represented by Structural Formulas (XIII) or (XIV):

- 12 -



(XIII)




(XIV)

In Structural Formulas (XIII) and (XIV), X₁, is as defined above for Structural Formulas (X) and (XI); n is an integer from two to five; W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;

In Structural Formulas (XIII) and (XIV), Ring A is substituted with R_a and R_b, wherein R_a and R_b are independently -H, a halogen, alkoxy or alkyl, or, taken together with ring A, form a naphthyl group; and R_a and R_b are independently -H, alkyl, aralkyl or, taken together with the nitrogen atom bonded to R_a and R_b, form a non-aromatic heterocyclic ring represented by a structure selected from:

15

-13-




R_5 is -H, alkanoyl, aroyl, aralkoyl, alkyl, aralkyl or cycloalkanoyl.

R_6 is an aryl group.

5 R_7 is -H or a heterocyclic ring.

In another embodiment of the present invention, the antagonist of chemokine receptor function is represented by Structural Formula (XVI):

-14-



(XVI)

5 A is $>NR_{14}$, $-O-$, $-S-$, $-CH_2-$, $-CH(R_{14})-$ or
 $-C(R_{14}R_{15})-$.

10 R₁₁ is -H, halogen, -CN, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -OH, -O-(aliphatic group), -O-(substituted aliphatic group), -S-(aliphatic group), -S-(substituted aliphatic group), -NO₂, -NH₂, -NH(aliphatic group), -NH(substituted aliphatic group), -N(aliphatic group)₂, -N(substituted aliphatic group)₂.

R₁₂ is an aromatic group or an aliphatic group.

15 Each R₁₃ is independently chosen and is -H, an aliphatic group or substituted aliphatic group. Thus, if n is greater than one, the R₁₃ attached to one double bond can be the same as or different from the R₁₃ substituents attached to the other double bonds. Structural Formula (XVI) indicates that each R₁₃ can be bonded to either 20 carbon atom in the double bond and that the stereochemistry of each double bond is independently selected and can be cis or trans.

n is an integer from one to about four.



B is $-N(R_{16})-$, $-S-$, $-O-$ or a covalent bond.

-15-


R_{14} , R_{15} and R_{16} are independently an aliphatic group or a substituted aliphatic group and can be the same or different.

5 Q is an aliphatic group, a substituted aliphatic group, a benzylic group, a substituted benzylic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.


10 In a preferred embodiment, n is 1 and B and Q are as defined above. In this instance, A is preferably $-O-$, $-S-$ or $>C(CH_3)_2$; B is $-N(R_{16})-$, $-S-$ or a covalent bond and R_{11} is preferably $-H$ or, when B is $-S-$, an aliphatic or substituted aliphatic group bonded to the same olefinic carbon atom as sulfur. As a consequence, the antagonist of 15 chemokine receptor function is a compound represented by one of Structural Formulas (XVII) through (XXV):



(XVII)





(XIX)





(XX)

-16-



(XXI)


(XXII)



(XXIII)

(XXIV)

5




(XXV)

In Structures (XVII) through (XXV), R₁₃ and R₁₆ are preferably an aliphatic group.

Alternatively, in Structural Formula XVI, B, Q and the terminal olefin carbon, taken together, form a non-aromatic


-17-

heterocyclic ring. The antagonist of chemokine receptor function is then represented by Structural Formula (XXVI) :




(XXVI)

5 R₁₁, R₁₂, R₁₃ and n are as described above for Structural Formula (XVI). Optionally, the non-aromatic heterocyclic ring in Structural Formula (XXVI), designated with a "D" and referred to herein as "Ring D", can be fused to an aromatic ring or substituted aromatic ring. The non-
 10 aromatic heterocyclic ring can be substituted or unsubstituted. In one example, Ring D is represented by the following structural formula:



15 In another embodiment of the present invention, the antagonist of chemokine receptor function is represented by Structural Formula (XXVII) :

-18-



(XXVII)

5 R_{21} is -OH, an aliphatic group, a substituted aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -O-CO-(aliphatic group) or -O-CO-(substituted aliphatic group). Preferably, R_{21} is -OH, CH_3CO-O- or an alkyl group substituted with CH_3NH- (e.g., an alkyl group substituted at the benzylic carbon 10 atom with methylamino methylene). Examples of R_{21} include -OH, CH_3CO-O- or $-CH(-CH(CH_3)_2)(-CH_2NHCH_3)$.

R₂₂ and R₂₃ are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -S-(aliphatic group), -S-(substituted aliphatic group), -O-(aliphatic group), -O-(substituted aliphatic group), -(CH₂)_n-R₂₆, and, taken together, can be a -(CH₂)₂- to -(CH₂)₅- alkylene group or a -(CH₂)₂- to -(CH₂)₅- alkylene group substituted with one or more aliphatic groups, substituted aliphatic groups, aromatic groups or substituted aromatic groups.

R₂₆ is a substituted or unsubstituted aromatic group.

- 19 -

In one aspect, the antagonist of chemokine receptor function is a compound represented by Structural Formula (XXVII), wherein:

5 R_{21} is -OH, an alkyl group, an alkoxy group, an acetoxy group or an alkyl group substituted with $-NR_{24}R_{25}$;


R_{22} and R_{23} are independently an alkyl group, an aromatic group, an aralkyl group, and ethylene- R_6 or thioalkyl, and, taken together, form an alkylene group;

10 R_{24} and R_{25} are independently an alkyl group, an aralkyl group and an aryl group;

R_{26} is a phenyl group substituted by R_1 , and R_{28} ; and

R_2 , and R_{28} are independently -H, -OH, alkoxy, or halogen.

15 In another embodiment of the present invention, the antagonist of chemokine function is a compound represented by Structural Formula (XXVIII):




(XXVIII)

20 R_{40} and R_{43} are independently an aliphatic group, a substituted aliphatic group, a benzylic group, a substituted benzylic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.

25 R_{41} and R_{42} are independently an aliphatic group or a substituted aliphatic group. Preferably, R_{41} and R_{42} are each a methyl group.

In another embodiment of the present invention, the antagonist of chemokine receptor function is a compound represented by Structural Formula (XXIX):

- 20 -



(XXIX)

R_{50} and R_{51} are independently -OH, a halogen, -O- (aliphatic group), -O-(substituted aliphatic group), -O-CO- (aliphatic group), -O-CO-(substituted aliphatic group), -NH₂, -NH(aliphatic group), -NH(substituted aliphatic group), -N(aliphatic group)₂, -N(substituted aliphatic group)₂, -S-(aliphatic group) or -S-(substituted aliphatic group). Preferably, R_{50} and R_{51} are independently -OH, a halogen, -O-(aliphatic group) or -O-(substituted aliphatic group).

R_{52} and R_{53} are independently -H, an aliphatic group, a substituted aliphatic group, a halogen, -NH₂, -NH(aliphatic group), -NH(substituted aliphatic group), -N(aliphatic group)₂ or -N(substituted aliphatic group)₂. Preferably, R_{52} and R_{53} are independently an aliphatic group, a substituted aliphatic group or a halogen.

Also included in the present invention are physiologically acceptable salts of the compounds represented by Structural Formulas (I) through (XXIX). Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the

-21-

like. Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like.

As used herein, aliphatic groups include straight 5 chained, branched or cyclic C₁-C₈ hydrocarbons which are completely saturated or which contain one or more units of unsaturation.

An "alkyl group" is a saturated aliphatic group, as defined above. The term "alkoxy" refers to an alkyl ether 10 chain with an alkyl group. "Alkanoyl" refers to alkyl substituted carbonyl; "aralkanoyl" refers to phenyl-alkyl-CO- and "aroyl" refers to arylcarbonyl including benzoyl, naphthoyl and the like. The term "halogen" means fluoro, chloro, bromo and iodo. The term 15 "aryl", as opposed to the term "aromatic group", means phenyl. The term "substituted phenyl" means aryl substituted by alkyl, halogen, alkoxy, nitro, amino, acetamido, cyano and trifluoromethyl and naphthyl. "Aralkyl" means -(CH₂)_x-phenyl, wherein x is an integer from 20 one to four including benzyl. It is noted that the terms "aromatic group", "carbocyclic aromatic group" and "heterocyclic aromatic group" are defined below and have different meanings from the term "aryl".










Aromatic groups include carbocyclic aromatic groups 25 such as phenyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl, and heterocyclic aromatic groups such as N-imidazolyl, 2-imidazole, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 2-pyranyl, 3-pyranyl, 3-pyrazolyl, 4-pyrazolyl, 30 5-pyrazolyl, 2-pyrazinyl, 2-thiazole, 4-thiazole, 5-thiazole, 2-oxazolyl, 4-oxazolyl and 5-oxazolyl.

Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl


-22-

rings. Examples include 2-benzothienyl, 3-benzothienyl, 2-benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2-benzothiazole, 2-benzooxazole, 2-benzimidazole, 2-quinolinyl, 3-quinolinyl, 1-isoquinolinyl, 3-quinolinyl, 1-isoindolyl, 3-isoindolyl, and acridintyl. Also included within the scope of the term "aromatic group", as it is used herein, is a group in which one or more carbocyclic aromatic rings and/or heteroaromatic rings are fused to a cycloalkyl or non-aromatic heterocyclic ring. Examples include decalin, phthalimido, benzodiazepines, benzooxazepines, benzooxazines, phenothiazines, and groups represented by the following structural formulas:

-23-



, or



-24-

Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The ring can be five, six, seven or eight-membered. Examples

5 include 2-tetrahydrofuryl, 3-tetrahydrofuryl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 10 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl and 4-thiazolidinyl.


"Heterocyclic ring", as opposed to "heteroaryl group" and "non-aromatic heterocyclic ring", is defined as imidazole, benzimidazole, pyridine, pyrimidine, thiazole, 15 benzothiazole, thienyl, benzothienyl. It is noted further the terms "heterocyclic aromatic group" and "non-aromatic heterocyclic ring" are defined above and have different meanings from the term "heterocyclic ring".

Suitable substituents on an alkyl, aliphatic, 20 aromatic, non-aromatic heterocyclic ring or benzyl group include, for example, -OH, halogen (-Br, -Cl, -I and -F) -O(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -CN, -NO₂, -COOH, -NH₂, -NH(aliphatic group, substituted aliphatic, 25 benzyl, substituted benzyl, aromatic or substituted aromatic group), -N(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -COO(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group), -CONH₂, -CONH(aliphatic, 30 substituted aliphatic group, benzyl, substituted benzyl, aromatic or substituted aromatic group), -SH, -S(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group) and -NH- 35 C(=NH)-NH₂. A substituted non-aromatic heterocyclic ring,

- 25 -

benzylic group or aromatic group can also have an aliphatic or substituted aliphatic group as a substituent. A substituted alkyl or aliphatic group can also have a non-aromatic heterocyclic ring, benzyl, substituted benzyl, 5 aromatic or substituted aromatic group as a substituent. A substituted non-aromatic heterocyclic ring can also have =O, =S, =NH or =N(aliphatic, aromatic or substituted aromatic group) as a substituent. A substituted aliphatic, substituted aromatic, substituted non-aromatic heterocyclic 10 ring or substituted benzyl group can have more than one substituent.

In the structural formulas depicted herein, the single or double bond by which a chemical group or moiety is connected to the remainder of the molecule or compound is 15 indicated by the following symbol:



For example, the corresponding symbol in Structural Formula (X) or (XI) indicates that the tricyclic ring system, which represents Z in Structural Formula (IX), is connected to 20 the alkylene group in Structural Formula (IX) by a single covalent bond between the alkylene group and the ring carbon in Ring C which is bonded to W.

A "subject" is preferably a mammal, such as a human, but can also be an animal in need of veterinary treatment, 25 e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).

A "therapeutically effective amount" of a compound is 30 an amount which results in the inhibition of one or more processes mediated by the binding of a chemokine to a receptor in a subject with a disease associated with

-26-

aberrant leukocyte recruitment and/or activation. Examples of such processes include leukocyte migration, integrin activation, transient increases in the concentration of intracellular free calcium $[Ca^{2+}]$, and granule release of 5 proinflammatory mediators. Alternatively, a "therapeutically effective amount" of a compound is a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with 10 a disease associated with aberrant leukocyte recruitment and/or activation.

The amount of compound administered to the individual will depend on the type and severity of the disease and on the characteristics of the individual, such as general 15 health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Typically, a therapeutically effective amount of the 20 compound can range from about 0.1 mg per day to about 100 mg per day for an adult. Preferably, the dosage ranges from about 1 mg per day to about 100 mg per day. An antagonist of chemokine receptor function can also be administered in combination with one or more additional 25 therapeutic agents, e.g. theophylline, β -adrenergic bronchodilators, corticosteroids, antihistamines, antiallergic agents and the like.

The compound can be administered by any suitable route, including, for example, orally in capsules, 30 suspensions or tablets or by parenteral administration. Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection. The compound can also be administered orally (e.g., 35 dietary), topically, by inhalation (e.g., intrabronchial,

-27-

intranasal, oral inhalation or intranasal drops), or rectally, depending on the disease or condition to be treated. Oral or parenteral administration are preferred modes of administration.

5 The compound can be administered to the individual in conjunction with an acceptable pharmaceutical carrier as part of a pharmaceutical composition for treatment of HIV infection, inflammatory disease, or the other diseases discussed above. Formulation of a compound to be
10 administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule). Suitable pharmaceutical carriers may contain inert ingredients which do not interact with the compound. Standard pharmaceutical formulation techniques can be
15 employed, such as those described in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. Suitable pharmaceutical carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate-
20 buffered saline, Hank's solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextran) are known in the art (Baker, et al., "Controlled Release of Biological
25 Active Agents", John Wiley and Sons, 1986).

The activity of compounds of the present invention can be assessed using suitable assays, such as receptor binding assays and chemotaxis assays. For example, as described in Exemplification Section, small molecule antagonists of
30 RANTES and MIP-1 α binding have been identified utilizing HL-60 (butyric acid differentiated) cells which bind RANTES and chemotax in response to RANTES and MIP-1 α as a model for leukocyte chemotaxis. Specifically, a high through-put receptor binding assay, which monitors ^{125}I -RANTES and

-28-




^{125}I -MIP-1 α binding to HL-60 cell membranes, was used to identify small molecule antagonists which block binding and RANTES and MIP-1 α mediated HL-60, T-cell, peripheral blood mononuclear cell, and eosinophil chemotactic response.

5 Compounds of the present invention can also be identified by virtue of their ability to inhibit the activation steps triggered by binding of a chemokine to its receptor, such as chemotaxis, integrin activation and/or granule mediator release.

10 The compounds represented by Structural Formula (IX), wherein Z is represented by Structural Formulas (IXa), (X) and (XI) and compounds represented by Structural Formulas (XIII) and (XIV) can be prepared according to methods described in *Collect. Czech. Chem. Commun.*, 50(5):1089-96

15 (1985) (CA 104:33990) and Czech Patent CS 240698 B1 870601 (CA 109:92794). The teachings of these references and references cited therein are incorporated herein by reference. For example, these compounds can be prepared by the following reaction scheme:

- 29 -



-30-


Compounds represented by Structural Formula (V) and (VI), for example, the compounds designated in Table 1 as L-380 and Table 2 as L-372, can be prepared according to methods described in *Collect. Czech. Chem. Commun.*,

5 *54* (7):1966-1978 (1989), Czech Patent CS-268400 (1991) and WO 90/13539, the teachings of which are incorporated herein by reference.


Compounds represented by Structural Formula (VII) and (VIII), for example, the compound designated as L-348 in 10 Table 2, can be prepared according to methods described in *Synth. Commun.* 25 (2):177-82 (1995), *Chem. Lett.*, (12):2295-8 (1994), *Ther. Drug. Monit.* 10 (2):177-83 (1988), *J. Med. Chem.* 28 (9):1319-24 (1985), U.S. Patent 4,086,234, U.S. Patent 15 4,012,514, U.S. Patent 3,936,468, U.S. Patent 3,922,266 and U.S. Patent 3,907,812, the teachings of which are incorporated herein by reference.

Compounds represented by Structural Formula (III) and (IV), for example the compound designates as L-377 in Table 20 2, can be prepared according to methods well known in the field of organic chemistry, for example, by reacting the sodium salt of a suitable phenol and a suitable alkylating agent. The phenol is preferably substituted with electron withdrawing groups (e.g., 3,4,5-trimethoxyphenol). This reaction is shown schematically below:

- 31 -



The phenol in the scheme above is preferably substituted with one or more electron withdrawing groups. The alkylating agent prepared, for example, by reacting a suitable bromo substituted acyl bromide (e.g., bromoacetyl bromide) with a suitable 1-substituted piperazine, for example, 1-benzylpiperazine, as shown below:



-32-

Compounds represented by Structural Formula (XII), for example, the compound designated L-347 in Table 1, can be prepared according to methods described in WO 97/11938, WO 97/09983, WO 96/40097, WO 96/39407 and EP 694543, 5 the teachings of which are incorporated herein by reference.

Compounds represented by Structural Formula (XVIII) and (XXI), for example the compound designated L-344 in Table 2, can be prepared, for example, by reacting a 1,3,3-trialkylindolinium anion with a suitable alkylating agent according to methods described in European Patent 94 EP 0400348 and U.S. Patent No. US 5,258,274, the teachings of which are incorporated herein by reference. By replacing the 1,3,3-trialkylindolinium anion with an appropriate 1-alkyl-benzoxazolinium anion or 1-alkyl-benzothiazolinium anion, similar procedures can be used to prepare compound represented by Structural Formulas (XVII), (XIX), (XX) and (XXII) through (XXV) (e.g., compounds designated as L-459 and L-464 in Table II). These 20 procedures are also suitable for preparing compounds represented by Structural Formula (XXVI), for example, the compound designated L-342 in Table 2, by using an appropriate alkylating agent.

Compounds represented by Structural Formula (XXVII), 25 for example, the compound designated L-381 in Table 1, can be prepared according to methods described in EP 757982, EP 533056, EP 457701, EP 434093 and EP 332064, the teachings of which are incorporated herein by reference. Other compounds represented by Structural 30 Formula (XXVII), for example, the compound designated L-345 in Table 1, can be prepared according to methods described in *Sb. Pr. Vyzk. Chem. Vyuziti Uhli, Dehtu Ropy* 7:21-39 (1967), *Z. Naturforsch. B: Anorg. Chem. Org. Chem* 34B(4):624-32 (1979) and *J. Med. Chem.* 26(6):823-31 (1983),

-33-

the teachings of which are incorporated herein by reference. Yet other compounds represented by Structural Formula (XXVII), for example, the compound designated L-349 in Table 1, can be prepared according to methods described 5 in EP 707007, WO 9501326, EP596692, EP 587050, EP 540165 and CA 2028031, the teachings of which are incorporated herein by reference.

Compounds represented by Structural Formula (XXVIII), for example, the compound designated L-339 in Table 1, can 10 be prepared according to methods described in WO 94/26302, *Collect. Czech. Chem. Commun.* 53(7):1424-60 (1988), EP 226448, ES 540861 and *Bull. Chem. Soc. Jap.* 44(6):1560-2, the teachings of which are incorporated herein by reference.

15 Compounds represented by Structural Formula (XXIX), for example, the compound designated L-319 in Table 1, can be prepared according to methods described in JP 09110771, *Polym. Mater. Sci. Eng.* 70:378-9 (1993), JP 03148232, JP 02286642, JP 03386641, JP 02248954, EP 342035, EP 307951, 20 *Eur. Polym. J.* 15(7):631-8 (1979), FR 2322161, *Izv. Akad. Nauk. SSSR. Ser. Khim.* (12):2808-10 (1973) and *Tetrahedron Lett.* (34):3707:10 (1968), the teachings of which are incorporated herein by reference.

25 The invention is illustrated by the following examples which are not intended to be limiting in any way.

EXEMPLIFICATION

Human eosinophils were prepared by isolation from the blood of donor individuals with high levels of circulating blood eosinophils (5-17%) by combining density gradient 30 centrifugation and negative selection with anti-CD16 magnetic beads (Hansel, T.T. *J. Immunol. Methods*, 122:97-

-34-

103 (1989)). Briefly, the granulocyte fraction from the Percoll centrifugation was incubated with CD16 micro beads (miniMACS, separation unit) for 30 minutes. Cells were then passed through a MACS column (Miltenyi Biotec, Inc.,
5 Auburn, CA) and eosinophils were collected in the flow through. Eosinophil purity was >99% as determined by analysis of Diff-Quik (Baxter) stained cytocentrifugation preparations by light microscopy.

10 HL-60 Cells, obtained from the American Type Culture Collection, were resuspended at 0.5 million cells/ml in equal proportions of RPMI-1640 and M199 (Gibco) with 20% fetal calf serum (FCS). After, addition of n-butyric acid (Sigma Chemical Co.) to a final concentration of 0.4 mM, cells were incubated for 4 days at 37°C, 5%CO₂, before use
15 in either whole cell chemotaxis assays or preparation for use as membranes for receptor binding assays.

Membrane Preparations for Chemokine Binding and Binding Assays

20 Membranes were prepared from n-butyric acid-treated HL60 cells. Cells were harvested by centrifugation, washed twice with PBS (phosphate-buffered saline), and the cell pellets were frozen at -70 to -85°C. The frozen pellet was thawed in ice-cold lysis buffer consisting of 5 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-sulfonic acid) pH 7.5, 2 mM EDTA (ethylenediaminetetraacetic acid), 5 µg/ml each aprotinin, leupeptin, and chymostatin (protease inhibitors), and 100 µg/ml PMSF (phenyl methane sulfonyl fluoride - also a protease inhibitor), at a concentration of 1 to 5 x 10⁷ cells/ml. This procedure results in cell
25 lysis. The suspension was mixed well to resuspend all of the frozen cell pellet. Nuclei and cell debris were removed by centrifugation of 400 x g for 10 minutes at 4°C.
30

-35-

The supernatant was transferred to a fresh tube and the membrane fragments were collected by centrifugation at 25,000 x g for 30 minutes at 4°C. The supernatant was aspirated and the pellet was resuspended in freezing buffer 5 consisting of 10 mM HEPES pH 7.5, 300 mM sucrose, 1 μ g/ml each aprotinin, leupeptin, and chymostatin, and 10 μ g/ml PMSF (approximately 0.1 ml per each 10⁸ cells). All clumps were resolved using a minihomogenizer, and the total 10 protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, CA, cat #500-0002). The membrane solution was then aliquoted and frozen at -70 to -85°C until needed.

Binding Assays utilized the membranes described above. Membrane protein (2 to 20 μ g total membrane protein) was 15 incubated with 0.1 to 0.2 nM ¹²⁵I-labeled RANTES or MIP-1 α with or without unlabeled competitor (RANTES or MIP-1 α) or various concentrations of compounds. The binding reactions were performed in 60 to 100 μ l of a binding buffer consisting of 10 mM HEPES pH 7.2, 1 mM CaCl₂, 5 mM MgCl₂, 20 and 0.5% BSA (bovine serum albumin), for 60 min at room temperature. The binding reactions were terminated by harvesting the membranes by rapid filtration through glass fiber filters (GF/B or GF/C, Packard) which were presoaked in 0.3% polyethyleneimine. The filters were rinsed with 25 approximately 600 μ l of binding buffer containing 0.5 M NaCl, dried, and the amount of bound radioactivity was determined by scintillation counting in a Topcount beta-plate counter.

Chemokines and Chemotaxis.

30 RANTES and MIP-1 α were purchased from Peprotech, Inc. Leukocyte chemotaxis was assessed on eosinophils, peripheral blood mononuclear cells, or HL60 cells

-36-

differentiated with butyric acid, using a modification of a transendothelial assay (Carr, M.W., et al. T.A., *Proc. Natl Acad Sci, USA*, **91**, 3652 (1994)). The endothelial cells used in this assay were the endothelial cell line, ECV 304, 5 obtained from the European collection of Animal Cell Cultures (Porton Downs, Salisbury, U.K.). Endothelial cells were cultured on 6.5 mm diameter Transwell culture inserts (Costar Corp., Cambridge, MA) with 3.0 μ m pore size. Culture media for the ECV 304 cells consisted of M199+10% 10 FCS, L-glutamine, and antibiotics. The assay media consisted of equal parts RPMI 1640 and M199 with 0.5% BSA. Two hours before the assay, 2×10^5 ECV 304 cells were plated onto each insert of the 24 well Transwell chemotaxis plate and incubated at 37°C. Chemotactic factors such as RANTES 15 or MIP-1 α (Peprotech) (diluted in assay medium) were added to the 24-well tissue culture plates in a final volume of 600 μ L. Endothelial-coated Transwells were inserted into each well and 10^6 cells of the leukocyte type being studied were added to the top chamber in a final volume of 100 μ L of 20 assay medium. The plate was then incubated at 37°C in 5% CO₂/95% air for 1-2h. The cells that had migrated to the bottom chamber were counted using flow cytometry. 500 μ L of the cell suspension from the lower chamber was placed in a tube and relative counts were obtained for a set period of 25 time of 30 seconds. This counting method was found to be highly reproducible and enabled gating on the leukocytes and the exclusion of debris or other cells. Counts obtained by this method matched closely those obtained by counting with a microscope. Assays evaluating chemotaxis inhibitors 30 were performed in the same way as control experiments above, except that inhibitor solutions, in assay media containing up to 1% of DMSO cosolvent, were added to both the top and bottom chambers prior to addition of the cells. Inhibitor potency was determined by comparison of cell

-37-

numbers migrated to the bottom chamber, with or without inhibitor. Control wells contained equivalent amounts of DMSO, but no inhibitor.

Ligand Binding Assay.

5 125 I-RANTES and 125 I-MIP-1 α were purchased from DuPont-NEN (Boston, MA) with a specific activity of 2,200 Ci/mM. Chemokine binding to the target cells, human eosinophils, was carried out using a modification of a method previously reported. (Van Riper, G.S.; *J. Exp. Med.* 177, 851-856
10 (1993)). Cells were washed once in PBS and resuspended in binding buffer (50mM HEPES, 1 mM CaCl₂, 5 mM MgCl₂, and 0.5% BSA) at a concentration of 1×10^7 / mL. Aliquots of 50 μ L (5×10^5 cells) were dispensed into microfuge tubes, followed by the addition of cold and radiolabelled
15 chemokines. The final reaction volume was 200 μ L. Nonspecific binding was determined by incubating cells with radiolabeled chemokines in the presence of increasing amounts of (250-500 nM) of cold chemokine. After 60-min incubation, at room temperature, the cells were washed 3x
20 with 1 mL of binding buffer plus 0.5 M NaCl. Cell pellets were then counted. All experiments were carried out using duplicates and repeated at least three times. Curve fit was calculated by Kaleidagraph software (Synergy Software, Reading, PA). Inhibition of binding was assessed by the
25 addition of test inhibitor compound at concentrations of 100 μ M final concentration, and incubation for 30 min prior to addition of the chemokine as above.

Inhibition of Peripheral Blood Mononuclear Cell (PBMC) Chemotaxis By Compounds L-370 and L-374

30 Cells were incubated with the concentrations of compound indicated in Figures 1A and 1B for 20 minutes at room temperature and were placed in the upper wells of the

-38-

chemotaxis chambers. Migration in response to MCP-1, RANTES, or MIP-1 α was assessed as described above.

Figure 1A is an illustration of the total number of cells migrating in response to the chemokines with and 5 without preincubation with different concentrations of L-370 or L-374. MCP-1 was used as a negative control to show the specificity of action of the compounds.

Figure 1B is an illustration of the results of the same experiments as in Figure 1A, expressed as percentage 10 inhibition, where the inhibition was calculated as cells migrated in the absence of compound/cells migrated in the presence of compound. 100% inhibition of migration occurred with 10.0 μ M and 1.0 μ M of L-370 and L-374, respectively.

15 The activities of other test compounds are reported in Tables 1-4 below as RBA, IC₅₀ or the inhibitor concentration required for 50% inhibition in receptor binding assays using ¹²⁵I-RANTES or ¹²⁵MIP-1 α as ligand and 20 HL60 cell membranes from cells differentiated by butyric acid (which chemotax in response to RANTES in an almost identical way described for eosinophils).

25 Leukocyte chemotaxis inhibition is expressed as percent inhibition of RANTES-induced chemotaxis using the same HL60 cells (butyric acid differentiated) at the indicated concentration (μ M) of compound.









- 39 -

Table 1

	L#	IC50 (μM)	Chemotaxis Inh
		Receptor Bind.	% Inhib @ μM
		Rantes MIP-1α	(HL60)
	L-381	11	12
		72% @ 2.5 μM	
		100% @ 5 μM	
	L-319	2.4	9
		31% @ 10 μM	
	L-345	9	12
		56% @ 8 μM	
	L-349	18	10
		not tested	
	L-347	12	7.6
		21 % @ 12 μM	
		90% @ 60 μM	
	L-380	14	8
		not tested	
	L-339	10	n.t. 5% @ 30 μM








- 40 -

Table 2

L#	RBA IC ₅₀ (μ M)	Inhibition HL60 Chemotaxis %Inhib'n, μ M
	Rantes MIP-1 α	
	L-377 2 0.6	66% @ 10 μ M
	L-339 10 23	not tested
	L-372 5.5 17	89% @ 6 μ M
	L-348 8 10	54% @ 4 μ M 103% @ 20 μ M
	L-342 6 \approx 12	74% @ 2 μ M
	L-344 5 15	67% @ 2 μ M
	L-459 3 13	92% @ 15 μ M
	L-464 35 \approx 10	not tested

-41-





Table 3

 L#	RBA IC50 (μM)		Leukocyte Chemoaxis (HL60 Cells) % Inhibition @ μM
	RANTES	MIP-1α	
 L-886	11.3	11.2	not tested
 L-804	>20	not tested	not tested
 L-374	0.2	0.36	81% @ 1 μM
 L-370	7.3	11.7	59% @ 2 μM 102% @ 10 μM
 L-887	>40	not tested	not tested
 L-378	21	33	not tested

-42-

Table 4

INHIBITION OF EOTAXIN-INDUCED EOSINOPHIL CHEMOTAXIS

	L#	Eosinophil Chemotaxis % Inhibition / μ M
	L-348	17% / 7 μ M 86% / 35 μ M
	L-377	100% / 3 μ M 100% / 6 μ M
	L-370	26% / 2 μ M 40% / 10 μ M
	L-374	IC50 = 45.5 μ M

-43-

Equivalents


Those skilled in the art will be able to recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific 5 embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

- 44 -

CLAIMS

What is claimed:

5 1. A method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to the individual a therapeutically effective amount of a compound represented by the following structural formula:



10 and physiologically acceptable salts thereof,
wherein:

Z is a substituted or unsubstituted aromatic group;

Y is a covalent bond, -O- or -CO-;

n is an integer from one to about five:


X is a covalent bond or -CO- ; and

R_a is an aliphatic or a substituted aliphatic group; and

R_b is an aliphatic group substituted with an aromatic group or substituted aromatic group; and wherein R_a and R_b , taken together with the nitrogen atom bonded to R_a and R_b , can form a substituted or unsubstituted non-aromatic heterocyclic ring.

2. The method of Claim 1 wherein the compound is represented by the following structural formula:

-45-




and physiologically acceptable salts thereof,
wherein:

M is >NR₂, >CR₁R₂, -O-, -S- or -CO-;

5 R₁ is -H, -OH, an aliphatic group, -O-(aliphatic group), -SH or -S-(aliphatic group);

10 R₂ is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.

3. The method of Claim 2 wherein the compound is represented by the following structural formula:




15 and physiologically acceptable salts thereof.

4. The method of Claim 3 wherein -Y- is -O- and -X- is -CO-.

20 5. The method of Claim 4 wherein n is one and R₂ is a C1 to about a C4 alkyl group substituted with an aromatic or substituted aromatic group.

6. The method of Claim 2 wherein the compound is represented by the following structural formula:

-46-




and physiologically acceptable salts thereof,
wherein R₁ is -H or -OH.

7. The method of Claim 6 wherein -Y- is -O- and -X- is
5 -CO-.

8. The method of Claim 7 wherein n is one and R₂ is C1 to
about a C4 alkyl group substituted with an aromatic or
substituted aromatic group.

9. The method of Claim 3 wherein the compound is
10 represented by the following structural formula:




and physiologically acceptable salts thereof.

10. The method of Claim 9 wherein n is 2 or 3 and R₂ is an
15 aliphatic or substituted aliphatic group.

11. The method of Claim 9 wherein the compound is
represented by the following structural formula:


- 47 -



and physiologically acceptable salts thereof.

12. The method of Claim 6 wherein the compound is represented by the following structural formula:


5



and physiologically acceptable salts thereof, wherein R_1 is -H or -OH.

13. The method of Claim 12 wherein n is two or three and R_2 is an aliphatic or substituted aliphatic group.

10 14. The method of Claim 3 wherein the compound is represented by the following structural formula:




and physiologically acceptable salts thereof.

-48-

15. The method of Claim 14 wherein n is 3 and R₂ is an aromatic group, a substituted aromatic group or an aliphatic group substituted with an aromatic or substituted aromatic group.

5 16. The method of Claim 6 wherein the compound is represented by the following structural formula:




and physiologically acceptable salts thereof.

10 17. The method of Claim 16 wherein n is 3 and R₂ is an aromatic group, a substituted aromatic group or an aliphatic group substituted with an aromatic or substituted aromatic group.

18. The method of Claim 2 wherein -X- and -Y- are each a covalent bond.

15 19. The method of Claim 18 wherein Z is represented by the following structural formula:




(IXa)

wherein:

-49-

5 Ring C is a substituted or unsubstituted C, or C₆ non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring and is bonded to the alkylene group by a single covalent bond between the alkylene group and a ring atom in Ring C which is not also in Ring A or Ring B.

20. The method of Claim 18 wherein Z is represented by a structural formula selected from:



10


wherein:

X₁ is a chemical bond, -S-, -CH₂- or -CH₂S-;

W is -H or an electron withdrawing group; and

15 wherein ring A and ring B are substituted or unsubstituted.

21. The method of Claim 20 wherein Z is represented by the following structural formula:




-50-

wherein Ring A and/or Ring B are substituted or unsubstituted.

22. The method of Claim 21 wherein M is $>NR_2$, $>C(OH)R_2$ or $>CHR_2$.

5 23. The method of Claim 22 wherein n is three and W is -CN.

24. The method of Claim 20 wherein Z is represented by the following structural formula:




10 wherein Ring A and/or Ring B are substituted or unsubstituted.

25. The method of Claim 24 wherein M is $>C(OH)R_2$ or $>CHR_2$.

26. The method of Claim 25 wherein W is -CN and n is three.

15 27. The method of Claim 1 wherein the compound is represented by a structural formula selected from:

-51-




and physiologically acceptable salts thereof.

28. The method of Claim 1 wherein:

-X- and -Y- are each a covalent bond;

-52-

Z is represented by a structural formula selected from:



5

wherein:

X₁ is a chemical bond, -S-, -CH₂- or -CH₂S-;


W is -H, -CN, alkylsulfonyl, carboxamido or carboxyalkyl;

n is an integer from 2-5;

10 Ring A is substituted with R_a and R_b, wherein R_a and R_b are independently -H, a halogen, alkoxy or alkyl, or, taken together with ring A, form a naphthyl group;

15 R_a and R_b are independently -H, alkyl, aralkyl or, taken together with the nitrogen atom bonded to R_a and R_b, form a non-aromatic heterocyclic ring represented by a structure selected from:

-53-




and physiologically acceptable salts thereof,
wherein:

5 R₅ is -H, alkanoyl, aroyl, aralkoyl, alkyl,
aralkyl or cycloalkyl;
R₆ is an aryl group; and
R₇ is -H or a heterocyclic ring.

29. The method of Claim 1 wherein the compound is
represented by the following structural formula:

10



and physiologically acceptable salts thereof.

-54-

30. The method of Claim 29; wherein:


n is an integer from about 2-4;

R_a is a C1 to about C4 substituted or unsubstituted alkyl group; and

R_b is -(CH₂)_m-R₁₀ wherein m is an integer from about 2-4 and R₁₀ is an aromatic group.

5

31. A method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to the individual a therapeutically effective amount of a compound represented by the following structural formula:



and physiologically acceptable salts thereof, wherein:

A is >NR₁₄, -O-, -S-, -CH₂-, -CH(R₁₄)- or -C(R₁₄,R₁₅)-;

R₁₁ is -H, halogen, -CN, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -OH, -O-(aliphatic group), -O-(substituted aliphatic group), -S-(aliphatic groups), -S-(substituted aliphatic groups), -NO₂, -NH₂, -NH(aliphatic group), -NH(substituted aliphatic group), -N(aliphatic group)₂, -N(substituted aliphatic group)₂;

20

R₁₂ an aromatic group or an aliphatic group;

25

-55-

each R_{13} is independently chosen and is -H, an aliphatic group or a substituted aliphatic group;

n is an integer from one to about four;

B is $-N(R_{16})-$, $-S-$, $-O-$ or a covalent bond; and

5 R_{14} , R_{15} and R_{16} are independently an aliphatic or substituted aliphatic group, and can be the same or different;

10 Q is an aliphatic group, a substituted aliphatic group, a benzylic group, a substituted benzylic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; and

15 wherein B, Q and the terminal olefin carbon, taken together, can form a substituted or unsusbstituted non-aromatic heterocyclic ring which is optionally fused to a substituted or unsubstituted aromatic group.

32. The method of Claim 31 wherein:

n is 1;


20 B is $-N(R_{16})-$, $-S-$, $-O-$ or a covalent bond; and

Q is an aliphatic group, a substituted aliphatic group, a benzylic group, a substituted benzylic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.

25

33. The method of Claim 31 wherein the compound is represented by the following structural formula:


- 56 -



and physiologically acceptable salts thereof.

34. The method of Claim 31 wherein the compound is represented by the following structural formula:


5



and physiologically acceptable salts thereof.


35. The method of Claim 31 wherein the compound is represented by the following structural formula:

- 57 -



and physiologically acceptable salts thereof.


36. The method of Claim 31 wherein the compound is
5 represented by the following structural formula:



and physiologically acceptable salts thereof.


-58-

37. The method of Claim 31 wherein the compound is represented by the following structural formula:



and physiologically acceptable salts thereof.


5 38. The method of Claim 31 wherein the compound is represented by the following structural formula:



and physiologically acceptable salts thereof.

10 39. The method of Claim 31 wherein the compound is represented by the following structural formula:


- 59 -



and physiologically acceptable salts thereof.

40. The method of Claim 31 wherein the compound is represented by the following structural formula:


5



and physiologically acceptable salts thereof.

41. The method of Claim 31 wherein the compound is represented by the following structural formula:


- 60 -



and physiologically acceptable salts thereof.

42. The method of Claim 31 wherein the compound is represented by the following structural Formula:


5



wherein Ring D is a substituted or unsubstituted non-aromatic heterocyclic ring which is optionally fused to a substituted or unsubstituted aromatic group.

10 43. A method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to the individual a therapeutically effective amount of a compound represented by the following structural formula:

-61-



and physiologically acceptable salts thereof,
wherein:

5 R₂₁ is -OH, an aliphatic group, a substituted aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -O-CO-(aliphatic group) or -O-CO-(substituted aliphatic group);

10 R₂₂ and R₂₃ are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -S-(aliphatic group), -S-(substituted aliphatic group), -O-(aliphatic group), -O-(substituted aliphatic group), -(CH₂)_n-R₂₆, and, taken together, can be a - (CH₂)₂- to -(CH₂)₅- alkylene group or a -(CH₂)₂- to -(CH₂)₅- alkylene group substituted with one or more aliphatic groups, substituted aliphatic groups, aromatic groups or substituted aromatic groups; and

15 R₂₆ is a substituted or unsubstituted aromatic group.

20

44. The method of Claim 43 wherein:

R₂₁ is -OH, an alkyl group, an alkoxy group, an acetoxy group or an alkyl group substituted with -NR₂₄R₂₅;

25 R₂₂ and R₂₃ are independently an alkyl group, an aromatic group, an aralkyl group, and ethylene-R₂₆ or thioalkyl, and, taken together, form an alkylene group;

- 62 -

R_{24} and R_{25} are independently an alkyl group, an aralkyl group and an aryl group;

R_{26} is a phenyl group substituted by R_2 , and R_{28} ; and

5 R_2 , and R_{28} are independently -H, -OH, alkoxy, or halogen.

45. The method of Claim 43 wherein:

10 R_{21} is -OH, CH_3CO-O- or an alkyl group substituted with CH_3NH- ;

R_{22} is thioalkyl, alkyl or phenyl; and

15 R_{23} is -H, methyl or, taken together with R_{22} , a propylene group, wherein the propylene group is unsubstituted or substituted with one or more methyl or ethyl groups.


46. The method of Claim 44 wherein:

R_{21} is -OH, CH_3CO-O- or $-CH(-CH(CH_3)_2)(-CH_2NHCH_3)$;

R_{22} is $-SC_6H_{15}$, methyl or phenyl; and

20 R_{23} is -H, methyl or, taken together with R_{22} , a $-CH_2CH_2C(CH_3)_2-$ group.

47. A method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation comprising administering to the individual a therapeutically effective amount of a compound represented by the following structural formula:



and physiologically acceptable salts thereof, wherein:


- 63 -

5 R₄₀ and R₄₃ are independently an aliphatic group, a substituted aliphatic group, a benzylic group, a substituted benzylic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;

R₄₁ and R₄₂ are independently an aliphatic group or a substituted aliphatic group.

48. The method of Claim 47 wherein R₄₁ and R₄₂ are each a 10 methyl group.

49. A method of treating a subject with a disease 15 associated with aberrant leukocyte recruitment and/or activation comprising administering to the individual a therapeutically effective amount of a compound represented by the following structural formula:



wherein:

20 R₅₀ and R₅₁ are independently -OH, a halogen, -O- (aliphatic group), -O-(substituted aliphatic group), -O-CO-(aliphatic group), -O-CO-(substituted aliphatic group), -NH₂, -NH(aliphatic group), -NH(substituted aliphatic group), -N(aliphatic group)₂, -N(substituted

-64-

aliphatic group),, -S-(aliphatic group) or -S-(substituted aliphatic group; and

5 R_{52} and R_{53} are independently -H, an aliphatic group, a substituted aliphatic group, a halogen, -NH₂, -NH(aliphatic group), -NH(substituted aliphatic group), -N(aliphatic group), or -N(substituted aliphatic group),.


50. The method of Claim 49 wherein:

10 R_{50} and R_{51} are independently -OH, a halogen, -O-(aliphatic group) or -O-(substituted aliphatic group); and

R_{52} and R_{53} are independently an aliphatic group, a substituted aliphatic group or a halogen.

15 51. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:

20



and physiologically acceptable salts thereof, wherein:

Z is a substituted or unsubstituted aromatic group;

25 Y is a covalent bond, -O- or -CO-;

n is an integer from one to about five;

X is a covalent bond or -CO-; and


- 65 -

R_a is an aliphatic or a substituted aliphatic group; and

5 R_b is an aliphatic group substituted with an aromatic group or substituted aromatic group; and wherein R_a and R_b , taken together with the nitrogen atom bonded to R_a and R_b , can form a substituted or unsubstituted non-aromatic heterocyclic ring.

52. The use of Claim 51 wherein Z is represented by a structural formula selected from:

10



or

wherein:

X_1 is a chemical bond, $-S-$, $-CH_2-$ or $-CH_2S-$;


15 W is $-H$, $-CN$, alkylsulfonyl, carboxamido or carboxyalkyl;

n is an integer from 2-5;

Ring A is substituted with R_a and R_b , wherein R_a and R_b are independently $-H$, a halogen, alkoxy or alkyl, or, taken together with ring A, form a naphthyl group;

20 R_a and R_b are independently $-H$, alkyl, aralkyl or, taken together with the nitrogen atom bonded to R_a and R_b , form a non-aromatic heterocyclic ring represented by a structure selected from:

- 66 -



and

and physiologically acceptable salts thereof,
wherein:


5 R₅ is -H, alkanoyl, aroyl, aralkoyl, alkyl,
aralkyl or cycloalkyl;

R₆ is an aryl group; and


R₇ is -H or a heterocyclic ring.

53. The use of Claim 51 wherein the compound is
10 represented by a structural formula selected from:

- 67 -




or



and physiologically acceptable salts thereof.

-68-

54. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:



and physiologically acceptable salts thereof, wherein:

10 A is $>NR_{14}$, -O-, -S-, -CH₂-, -CH(R₁₄)- or -C(R₁₄R₁₅)-;

15 R₁₁ is -H, halogen, -CN, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -OH, -O-(aliphatic group), -O-(substituted aliphatic group), -S-(aliphatic groups), -S-(substituted aliphatic groups), -NO₂, -NH₂, -NH(aliphatic group), -NH(substituted aliphatic group), -N(aliphatic group)₂, -N(substituted aliphatic group)₂;

20 R₁₂ an aromatic group or an aliphatic group; each R₁₃ is independently chosen and is -H, an aliphatic group or a substituted aliphatic group;

n is an integer from one to about four;

B is -N(R₁₆)-, -S-, -O- or a covalent bond; and

-69-


R_{14} , R_{15} and R_{16} are independently an aliphatic or substituted aliphatic group, and can be the same or different;

5 Q is an aliphatic group, a substituted aliphatic group, a benzylic group, a substituted benzylic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; and

10 wherein B , Q and the terminal olefin carbon, taken together, can form a substituted or unsubstituted non-aromatic heterocyclic ring which is optionally fused to a substituted or unsubstituted aromatic group.

15 55. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:

20



25 and physiologically acceptable salts thereof,
wherein:

25 R_{21} is $-OH$, an aliphatic group, a substituted aliphatic group, $-O-$ (aliphatic group), $-O-$ (substituted aliphatic group), $-O-CO-$ (aliphatic group) or $-O-CO-$ (substituted aliphatic group);

-70-

R₂₂ and R₂₃ are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -S-(aliphatic group), -S-(substituted aliphatic group),
5 -O-(aliphatic group), -O-(substituted aliphatic group), -(CH₂)_n-R₂₆, and, taken together, can be a -(CH₂)₂- to -(CH₂)₅- alkylene group or a -(CH₂)₂- to -(CH₂)₅- alkylene group substituted with one or more aliphatic groups, substituted aliphatic groups,
10 aromatic groups or substituted aromatic groups; and R₂₆ is a substituted or unsubstituted aromatic group.

56. The use of Claim 55 wherein:

15 R₂₁ is -OH, an alkyl group, an alkoxy group, an acetoxy group or an alkyl group substituted with -NR₂₄R₂₅;

20 R₂₂ and R₂₃ are independently an alkyl group, an aromatic group, an aralkyl group, and ethylene-R₂₆ or thioalkyl, and, taken together, form an alkylene group;


R₂₄ and R₂₅ are independently an alkyl group, an aralkyl group and an aryl group;

R₂₆ is a phenyl group substituted by R₂₇ and R₂₈; and

25 R₂₇ and R₂₈ are independently -H, -OH, alkoxy, or halogen.

57. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:

- 71 -




wherein:

R₅₀ and R₅₁ are independently -OH, a halogen, -O- (aliphatic group), -O- (substituted aliphatic group), -O-CO- (aliphatic group), -O-CO- (substituted aliphatic group), -NH₂, -NH (aliphatic group), -NH (substituted aliphatic group), -N (aliphatic group)₂, -N (substituted aliphatic group)₂, -S- (aliphatic group) or -S- (substituted aliphatic group); and

R₅₂ and R₅₃ are independently -H, an aliphatic group, a substituted aliphatic group, a halogen, -NH₂, -NH (aliphatic group), -NH (substituted aliphatic group), -N (aliphatic group)₂ or -N (substituted aliphatic group)₂.

15 58. Use of a compound for the manufacture of a medicament for the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:

- 72 -



and physiologically acceptable salts thereof,
wherein:

5 R_{40} and R_4 , are independently an aliphatic group, a substituted aliphatic group, a benzylic group, a substituted benzylic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group;

10 R_{41} and R_{42} are independently an aliphatic group or a substituted aliphatic group.

59. A pharmaceutical composition comprising the compound of Claim 31 and a suitable pharmaceutical carrier.

60. A pharmaceutical composition comprising the compound of Claim 43 and a suitable pharmaceutical carrier.

15 61. A pharmaceutical composition comprising the compound of Claim 44 and a suitable pharmaceutical carrier.


62. A pharmaceutical composition comprising the compound of Claim 47 and a suitable pharmaceutical carrier.

20 63. A pharmaceutical composition comprising the compound of Claim 49 and a suitable pharmaceutical carrier.

64. A compound for use in the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation,

- 73 -

and said compound being represented by the following structural formula:



and physiologically acceptable salts thereof,

5 wherein:

A is $>NR_{14}$, $-O-$, $-S-$, $-CH_2-$, $-CH(R_{14})-$ or
 $-C(R_{14}R_{15})-$;

10 R_{11} is $-H$, halogen, $-CN$, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, $-OH$, $-O-$ (aliphatic group), $-O-$ (substituted aliphatic group), $-S-$ (aliphatic groups), $-S-$ (substituted aliphatic groups), $-NO_2$, $-NH_2$, $-NH$ (aliphatic group), $-NH$ (substituted aliphatic group), $-N$ (aliphatic group), $-N$ (substituted aliphatic group);

15 R_{12} an aromatic group or an aliphatic group;

each R_{13} is independently chosen and is $-H$, an aliphatic group or a substituted aliphatic group;

n is an integer from one to about four;

20 B is $-N(R_{16})-$, $-S-$, $-O-$ or a covalent bond; and

R_{14} , R_{15} and R_{16} are independently an aliphatic or substituted aliphatic group, and can be the same or different;


25 Q is an aliphatic group, a substituted aliphatic group, a benzylic group, a substituted benzylic group, an aromatic group, a substituted aromatic group, a

-74-

non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group; and

wherein B, Q and the terminal olefin carbon, taken together, can form a substituted or unsubstituted non-aromatic heterocyclic ring which is optionally fused to a substituted or unsubstituted aromatic group.

5 65. A compound for use in the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:



15 and physiologically acceptable salts thereof, wherein:

20 R₂₁ is -OH, an aliphatic group, a substituted aliphatic group, -O-(aliphatic group), -O-(substituted aliphatic group), -O-CO-(aliphatic group) or -O-CO-(substituted aliphatic group);

25 R₂₂ and R₂₃ are independently -H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, -S-(aliphatic group), -S-(substituted aliphatic group), -O-(aliphatic group), -O-(substituted aliphatic group), -(CH₂)_n-R₂₆, and, taken together, can be a -(CH₂)₂- to -(CH₂)₅- alkylene group or a -(CH₂)₂- to -(CH₂)₅- alkylene group substituted with one or more

-75-

aliphatic groups, substituted aliphatic groups, aromatic groups or substituted aromatic groups; and
R₂₆ is a substituted or unsubstituted aromatic group.

5 66. The compound of Claim 65 wherein:

R₂₁ is -OH, an alkyl group, an alkoxy group, an acetoxyl group or an alkyl group substituted with -NR₂₄R₂₅;

10 R₂₂ and R₂₃ are independently an alkyl group, an aromatic group, an aralkyl group, and ethylene-R₂₆ or thioalkyl, and, taken together, form an alkylene group;


R₂₄ and R₂₅ are independently an alkyl group, an aralkyl group and an aryl group;

15 R₂₆ is a phenyl group substituted by R₂₇ and R₂₈; and

R₂₇ and R₂₈ are independently -H, -OH, alkoxy, or halogen.

67. A compound for use in the treatment or prevention of a
20 disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:

- 76 -




wherein:

5 R_{50} and R_{51} are independently -OH, a halogen, -O- (aliphatic group), -O-(substituted aliphatic group), -O-CO- (aliphatic group), -O-CO- (substituted aliphatic group), -NH₂, -NH(aliphatic group), -NH(substituted aliphatic group), -N(aliphatic group)₂, -N(substituted aliphatic group)₂, -S-(aliphatic group) or -S- (substituted aliphatic group; and

10 R_{52} and R_{53} are independently -H, an aliphatic group, a substituted aliphatic group, a halogen, -NH₂, -NH(aliphatic group), -NH(substituted aliphatic group), -N(aliphatic group)₂ or -N(substituted aliphatic group)₂.

15 68. A compound for use in the treatment or prevention of a disease in a subject, said disease being associated with aberrant leukocyte recruitment and/or activation, and said compound being represented by the following structural formula:

20



- 77 -

and physiologically acceptable salts thereof,
wherein:

5 R₄₀ and R₄₃ are independently an aliphatic group, a
substituted aliphatic group, a benzylic group, a
substituted benzylic group, an aromatic group, a
substituted aromatic group, a non-aromatic
heterocyclic group or a substituted non-aromatic
heterocyclic group;

10 R₄₁ and R₄₂ are independently an aliphatic group or
a substituted aliphatic group.

1/1




FIG. 1A




FIG. 1B

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/13, 31/135, 31/445, 31/495, 31/535, 31/54, 31/38		A3	(11) International Publication Number: WO 98/02151
			(43) International Publication Date: 22 January 1998 (22.01.98)
(21) International Application Number: PCT/US97/12120		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 July 1997 (11.07.97)			
(30) Priority Data: 60/021,716 12 July 1996 (12.07.96) US			
(71) Applicant: LEUKOSITE, INC. [US/US]; 215 First Street, Cambridge, MA 02142 (US).			
(72) Inventors: SCHWENDER, Charles, F.; 577 East Hill Road, Glen Gardner, NJ 08826 (US). MACKAY, Charles, R.; 126 Church Street, Watertown, MA 02172 (US). PINTO, Julia, C.; 8 Chubb's Brook Lane, Beverly Farms, MA 01915 (US). NEWMAN, Walter; 8 Durham Street No. 3, Boston, MA 02115 (US).			
(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02173 (US).		(88) Date of publication of the international search report: 25 June 1998 (25.06.98)	

(54) Title: CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR

(57) Abstract

Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by structural formula (I) and physiologically acceptable salts thereof. Z is a substituted or unsubstituted aromatic group. Y is a covalent bond, -O- or -CO-. n is an integer from one to about five. X is a covalent bond or -CO-. R_a is an aliphatic or a substituted aliphatic group; R_b is an aliphatic group substituted with an aromatic group or substituted aromatic group; and, taken together with the nitrogen atom bonded to R_a and R_b, can form a substituted or unsubstituted non-aromatic heterocyclic ring.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

National Application No.
PCT/US 97/12120

A. CLASSIFICATION OF SUBJECT MATTER

A 61 K 31/13, A 61 K 31/135, A 61 K 31/445, A 61 K 31/495,
A 61 K 31/535, A 61 K 31/54, A 61 K 31/38

According to International Patent Classification (IPC) or to both national classification and IPC 6

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HELWIG, H. et al. Arznei-mittel. Stuttgart: Helwig/Otto Arzneimittel, 1992. Vol. 1, 8th edition, pages 4-1 to 4-24, especially 4-8: Thiethylparazin. --	1-3, 6, 18, 19, 51
A	Chem. abstr., Vol. 104, No. 5, 03 February 1986 (Columbus, Ohio, USA), page 540, column 2, the abstract No. 33990s, SINDELAR, K. et al. "Potential anti-diarrheal agents: 1-(11-cyano-6,11-dihydrodibenzo(b,e)-thiepin-11-ylalkyl)-and 1-(10-cyano-10,11-dihydrodibenzo(b,f)thiepin-10-ylalkyl)-4-substituted piperi-	1, 2, 6, 18-29, 51-53

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *B* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search:

03 November 1997

Date of mailing of the international search report

04.05.98

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

MAZZUCCO e.h.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/12120

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	dines," Collect. Czech. Chem. Commun. 1985, 50(5), 1089-96 (Eng) (cited in the application). --	
A	Chem. abstr., Vol. 109, No. 11, 12 September 1988 (Columbus, Ohio, USA), page 689, column 2, the abstract No. 92794g, PROTIVA, M. et al. "Substituted 11-(pi- peridinoalkyl)-6,11-dihy- drodibenz(b,e)thiepin-11- -carbonitriles useful as antidiarrheal drugs," Czech. CS 240,698 (cited in the application). --	1, 2, 6, 18-23, 27-29, 51-53
A	WO 90/13539 A1 (MEIJI SEIKA KAISHA, LTD.) 15 November 1990 (15.11.90), abstract (cited in the application). --	1-3, 9- 10, 51
A	US 4086234 A (DRYDEN, H.L. et al.) 25 April 1978 (25.04.78), abstract, claims 1,4,5, examples 2-4 (cited in the application). --	1, 2, 6, 16, 17, 51
A	US 3922266 A (KATSUBE, J. et al.) 25 November 1975 (25.11.75), abstract, column 1, line 1 - column 2, line 23, column 3, lines 14-18 (cited in the application). --	1, 2, 3, 6, 14- 17, 51
A	US 3936468 A (YAMAMOTO, H. et al.) 03 February 1976 (03.02.76), abstract, column 1, lines 6-60 (cited in the application). --	1, 2, 6, 16, 17, 51
A	US 3907812 A (YAMAMOTO, H. et al.) 23 September 1975 (23.09.75), abstract, column 1, lines 15-67 (cited in the application). ----	1, 2, 6, 16, 17, 51

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/12120

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-50 because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-50 are directed to a method of treatment of the human or the animal body by therapy, the search has been carried out for the matter of claims 1-30 and has been based on the alleged effects of the composition (see PCT Rule 39.1 (iv)).
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Subject 1: 1-30, 51-53
Subject 2: 31-42, 54, 59, 64
Subject 3: 43-46, 55, 56, 60, 61, 65, 66
Subject 4: 47, 48, 58, 62, 68
Subject 5: 49-50, 57, 63, 67

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-30, 51-53

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

ANHANG

- zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

ANNEX

to the International Search Report to the International Patent Application No.

ANNEXE

au rapport de recherche international relatif à la demande de brevet international n°

PCT/US 97/12120 SAE 166629

In diesem Anhang sind die Mitglieder der Patentfamilien der im obenge-nannten internationalen Recherchenbericht angeführten Patentdokumente angegeben. Diese Angaben dienen nur zur Unter-richtung und erfolgen ohne Gewähr.

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The Office is in no way liable for these particulars which are given merely for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche interna-tional visée ci-dessus. Les renseigne-ments fournis sont donnés à titre indica-tif et n'engagent pas la responsabilité de l'Office.

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9013539	15-11-90	keine - none - rien	
US A 4086234	25-04-78	AU A1 19297/76 AU B2 507682 CA A1 1064926 CH A 621113 DE A1 2650961 DE B2 2650961 FR A1 230677 FR B1 230677 GB A 14051990 JP A2 52059163 JP B4 62024428 NL A 76122324 SE A 76122379 SE B 428469 SE C 428469	11-05-78 21-02-80 23-10-79 10-01-81 10-05-77 06-05-89 06-06-77 10-06-82 10-02-78 16-05-77 28-05-87 10-05-77 08-05-77 04-07-83 14-10-83
US A 3922266	25-11-75	BE A1 792906 CA A1 994349 CH A 589661 DE A1 2261269 DE B1 2265095 DE B2 2265094 DE B3 2261269 DE B4 2265095 FI A1 579 FR B1 2163717 GB A 1407706 HU P 1652508 JP A2 4903491 SE B 399707 SE C 399707 US A 4012514 AT A 10762/72 AT B 3368444 HU P 168117 JP A3 4903036 JP B4 5800981 HU P 168116 JP A2 4903037 JP B4 580010907 SE A 7508230 AT A 1588775 AT B 1301726 CH A 593296 JP A2 49061130 US A 4012515 JP A3 490015500 JP A4 480089569 JP B4 550035390 JP A2 480081854 JP B4 550044749 JP A2 480067284 JP B4 580012273 FR A1 2163717 JP A2 48007283 JP B4 58020996	18-06-73 02-08-76 15-07-77 28-06-73 11-03-76 15-04-76 18-10-79 24-07-80 12-11-81 10-11-80 15-07-77 24-09-75 27-07-74 05-03-74 27-02-78 08-05-78 15-03-77 15-06-75 28-02-76 18-03-74 26-04-83 18-07-70 15-09-75 01-09-83 28-02-76 18-03-74 26-04-83 18-07-70 15-09-75 25-06-76 30-11-77 15-08-74 15-03-77 08-01-74 15-11-73 12-09-80 01-11-73 13-11-80 15-09-73 07-03-83 27-07-73 13-09-73 26-04-83
US A 3936468	03-02-76	AT B 303728 BE A1 757994 CA A1 974240 CA A2 983031 CH A P 545207 CH P 1592271 DE A 20052337 DE B 20052337 DE C 20052337	11-12-72 09-09-89 09-09-75 03-02-75 31-01-74 27-12-74 03-09-71 16-09-75 03-04-76

1	4	7	10	13	16	19	22	25	28	31	34	37	40	43	46	49	52	55	58	61	64	67	70	73	76	79	82	85	88	91	94	97	100
1	4	7	10	13	16	19	22	25	28	31	34	37	40	43	46	49	52	55	58	61	64	67	70	73	76	79	82	85	88	91	94	97	100
1	4	7	10	13	16	19	22	25	28	31	34	37	40	43	46	49	52	55	58	61	64	67	70	73	76	79	82	85	88	91	94	97	100
1	4	7	10	13	16	19	22	25	28	31	34	37	40	43	46	49	52	55	58	61	64	67	70	73	76	79	82	85	88	91	94	97	100
1	4	7	10	13	16	19	22	25	28	31	34	37	40	43	46	49	52	55	58	61	64	67	70	73	76	79	82	85	88	91	94	97	100

keine - none - rien

US A 3907812 23-09-75